AG
Agios
AGIO·NASDAQCambridge MAFounded 2008500 employees
Mid CapbiotechPublicRare DiseaseHematology
Platform: Cell Metab
Market Cap
$3.5B
All Drugs
3
Clinical Trials
6
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (AGIO)
Loading AGIO stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Rimanaritide | AGI-2359 | Phase 1 | 2 | CDK4/6 | Wilms | ||
| Liraratamab | AGI-5092 | Phase 3 | 1 | SGLT2 | Cervical CaMelanoma | ||
| AGI-4446 | AGI-4446 | Phase 3 | 3 | PSMA | LGS |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (7)